Cost and Outcome Analysis of Autologous Peripheral Blood Stem Cell Mobilization with Plerixafor and G-CSF vs. Cyclophosphamide and G-CSF in Patients with Multiple Myeloma: A Reassessment in View of Increased Costs of Cyclophosphamide